婴儿期RSV感染相关抗生素使用:国际前瞻性出生队列研究
RESCEU出生队列纳入五个欧洲国家9154名健康足月婴儿,随访第一年RSV-ARI住院情况;嵌套队列993人主动监测RSV季节的ARI。总队列中22.8%的RSV住院和62.5%的RSV重症监护入院使用了抗生素;估计1.3%的健康足月婴儿在第一年因RSV感染接受至少一个疗程抗生素,RSV占RSV季节ARI抗生素处方的22.9%。
要点
- 总队列中22.8%的RSV住院(33/145)和62.5%的RSV重症监护入院(5/8)使用了抗生素。
- 嵌套队列中5.2%的任何严重度RSV-ARI(13/250)和9.9%的需医疗就诊RSV-ARI(13/131)使用了抗生素。
- 估计1.3%(95%CI: 0.8-2.0)的健康足月婴儿在第一年接受至少一个疗程的RSV相关抗生素。
核心结论
- 每77名健康足月婴儿中约有1名在满一岁前因RSV感染接受抗生素治疗。
- RSV占RSV季节ARI抗生素处方的22.9%。
- 需要真实世界证据来确定RSV免疫接种对婴儿期抗生素使用的影响。
研究设计与样本
- RESCEU出生队列研究为国际前瞻性出生队列,随访2017年7月1日至2020年7月31日五个欧洲国家出生的健康足月婴儿(n=9154),识别婴儿期RSV-ARI住院。
- 嵌套队列(n=993)在RSV季节(10月至4月)出现ARI症状时采集鼻拭子进行主动RSV监测。
- 住院期间抗生素使用通过病历审查确定,门诊数据通过父母问卷收集。
主要发现
- 总队列中,RSV住院的抗生素使用比例为22.8%(33/145),RSV重症监护入院的抗生素使用比例为62.5%(5/8)。
- 嵌套队列中,任何严重度RSV-ARI的抗生素使用比例为5.2%(13/250),需医疗就诊RSV-ARI的抗生素使用比例为9.9%(13/131)。
- 健康足月婴儿第一年接受至少一个疗程RSV相关抗生素的估计发生率为1.3%(95%CI: 0.8-2.0)。
- RSV相关抗生素处方发生率为每1000婴儿月1.1次(95%CI: 0.6-1.9)。
- RSV占RSV季节ARI抗生素处方的22.9%。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early-life antibiotic use impacts microbiome composition and contributes to the emergence of antimicrobial resistance. Despite respiratory syncytial virus (RSV) being a leading cause of acute respiratory infections (ARI), accurate estimates of antibiotic use attributable to RSV are lacking. OBJECTIVES: To assess RSV-associated antibiotic use during the first year of life. PATIENTS AND METHODS: The RESCEU birth cohort study followed healthy term infants, born (n = 9154) between 1 July 2017 and 31 July 2020 from five European countries, to identify RSV-ARI hospitalizations during infancy. In a nested cohort (n = 993), we performed active RSV surveillance by collecting nasal swabs in case of ARI symptoms during RSV seasons (October-April). Antibiotic use during hospitalization was identified through chart review, while outpatient data were collected via parental questionnaires. RESULTS: In the total cohort, antibiotics were used in 22.8% of RSV hospitalizations (33/145) and 62.5% of RSV intensive care admissions (5/8). In the nested cohort, antibiotics were used in 5.2% of any-severity RSV-ARI (13/250) and 9.9% of medically attended RSV-ARI (13/131). This results in an estimated incidence of 1.3% (95%CI: 0.8-2.0) of healthy term infants receiving ≥1 course of antibiotics associated with RSV infection in their first year, with an incidence rate of 1.1 RSV-associated antibiotic prescriptions per 1000 infant-months (95%CI: 0.6-1.9). As such, RSV accounts for 22.9% of antibiotic prescriptions for ARI during RSV seasons. CONCLUSIONS: One in 77 healthy term infants receives antibiotics during RSV infection before their first birthday. Real-world evidence is needed to establish the impact of RSV immunization on antibiotic use during infancy. CLINICAL TRIALS REGISTRATION: NCT03627572.
引用
- Hak SF, Venekamp RP, Billard MN, et al. Antibiotic use attributable to RSV infections during infancy-an international prospective birth cohort study. J Antimicrob Chemother. 2025. PMID: 40343736. doi:10.1093/jac/dkaf123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。